Europe
Access to medicines and the EU as a place of innovation are the goals of the EU’s medicines strategy, Kyriakides said.
freddieduvauchelle8 mins ago
Facebook Twitter LinkedIn Tumblr Pinterest Reddit
A small EU country like Cyprus can achieve much more for its citizens if it has a big European family to rely on, said EU Health Commissioner Stella Kyriakides on Friday at a meeting in Nicosia. said in a speech at a conference on the Cyprus health care system. The Cyprus Research and Development Pharmaceutical Companies Association (Kefea) cooperates with the European Federation of Pharmaceutical Industry Associations (Efpia).
In a speech at a conference titled ‘A New Era of Healthcare in Cyprus: Accepting, Assessing and Evolving’, Kyriakides emphasized the importance of cooperation at EU level in addressing healthcare challenges such as the Covid-19 pandemic. Having said that, we will provide quality health care to all citizens of the block.
“In a true European Health Union, patients should always have access to the medicines they need, wherever they live,” she said, referring to the EU’s medicines strategy.
“Their medicines have to be available and affordable,” she said, adding that the pharmaceutical industry should be given the necessary conditions to thrive and remain a global leader. rice field.
“To me, making sure our patient’s needs are met is a top priority,” she said.
The Commissioner said the Pharmaceuticals Strategy includes more than 50 actions, both legislative and non-legislative, aimed at ensuring this fundamental objective.
To achieve this, “we will work with our industry partners to strengthen security of supply, address systemic problems related to shortages of medicines, and enable innovation and production of medicines in Europe.” We are building a flexible regulatory framework that
Ultimately, the pharmaceutical strategy is for both patients and the industry, she said. “We are putting patients at the heart of our pharmaceutical policy at every step, ensuring that the EU pharmaceutical industry remains competitive and innovative,” she added.
The Commissioner also said Europe can and should be a leader in research, development and innovation, but said that for innovation to have any value it needs to reach patients. rice field.
A good example of this is in the field of rare diseases, where 95% of these diseases have no cure.
“That is why, as part of our EU pharmaceutical strategy, we are reviewing current regulations to encourage innovation, especially where it is most needed, and to address the unmet needs of patients across the EU.” she said.
This vision is “at the heart of the European Health Union, which represents our major response to the COVID-19 pandemic,” she added.
The Commissioner also said that building the European Health Union is not only about being prepared to respond to crises, but also about building tomorrow’s sustainable health systems and providing better care for EU patients. I said yes.
She said the success of initiatives ranging from the upcoming reform of pharmaceutical regulations to the EU Cancer Plan, digital health and flagships of all European Health Unions will depend on collaboration, trust and vision.
The Commissioner said a strong European Health Union would also be a necessary step for a strong Cyprus health system, but a small EU country like Cyprus said, “If you have a large European family to rely on, your citizens will be better off. You can accomplish a lot more because of it.”
Cyprus Health Minister Michalis Hadjipantera said in his own video message that promoting reforms is a “one-way street” and that his ministry considers constructive criticism as well as the positions of all institutions with a purpose. Improving the functioning and efficiency of health care structures for the benefit of said societies. He also mentioned the establishment of a national pharmacy that will contribute to the modernization of Cyprus’ healthcare delivery system in the near future.
Meanwhile, Kefea Chairman Kyriakos Mikellis said in his speech that the conference was “very important” as it marks a turning point in the healthcare sector in both Cyprus and the European Union. He said the commission’s efforts to amend the EU’s pharmaceutical law are “key to the future of the health sector and access to medicines, not only in Cyprus, but across Europe”.
He also referred to the implementation of Cyprus’ general health system three years ago, saying that while the new system “has significantly improved the supply and control of medicines in primary care”, there are still many deficiencies in the second-tier health system. I pointed out that there is an open issue. Introduction of systems and innovative medicines and treatments.
Michelisz believes that solutions that lead to a sustainable healthcare system and at the same time ensure access to quality services and innovative medicines can only be achieved through open dialogue, respect and participation of all stakeholders in the process. We have expressed our belief that we can reach it.
https://cyprus-mail.com/2022/11/11/access-to-medicines-and-eu-as-a-place-of-innovation-are-eu-pharmaceutical-strategy-goals-says-kyriakides/ Access to medicines and the EU as a place of innovation are the goals of the EU’s medicines strategy, Kyriakides said.
